Humira In 2023: The $17bn Biosimilar Opportunity
Landmark LOE Looms In US; Several Adalimumab Launches Expected Throughout Year
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
